Biotech Startups

Emotiv develops wearable EEG systems and software platforms that capture and analyze brain signals to support neuroscience research, brain-computer interfaces, and cognitive AI applications. The platform serves researchers, developers, and organizations seeking to understand brain function and enable human-computer interaction.

1 investor

Empirico discovers and develops siRNA medicines designed to mimic naturally-occurring genetic variants that have beneficial effects on health and disease. Using its human genetics and siRNA chemistry platforms, the company advances a pipeline of clinical and preclinical precision medicine programs targeting common diseases with unmet need.

1 investor

Empress provides drug discovery teams with an industrialized Perturb-seq platform that combines CRISPR-based single-cell functional genomics, chemoproteomics, and multi-omics with causal machine learning to identify what drives activity, efficacy, and risk. It serves pharmaceutical and biotech R&D teams seeking mechanistic understanding of drug targets.

1 investor

Emtora Biosciences is a clinical-stage life science company developing eRapa, a novel formulation of rapamycin, to prevent the onset and recurrence of cancer. Its lead program, Serenta (eRapa), is in a Phase 3 trial evaluating safety and efficacy in patients diagnosed with familial adenomatous polyposis (FAP).

1 investor

Emulsi develops NanoLIPID™, a natural lipid technology that self-assembles into nano-structures for encapsulating active pharmaceutical ingredients, nutraceuticals, and bioactive compounds. The platform targets oral drug delivery, cosmetics, and nutraceutical applications.

1 investor

EmVenio runs decentralized clinical research through in-home patient visits, community-based research sites, and patient navigation services, helping trial sponsors and CROs reach underrepresented populations. It supports clinical trial recruitment, retention, and data capture across more than 90 countries.

1 investor

Enable Medicine builds an integrated biological data platform that organizes and links clinical, spatial, cellular, and molecular data from patients and studies into a unified index to accelerate therapeutic discovery and diagnostics for researchers.

1 investor

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need. Its work has contributed to hepatitis C virus combination therapies, and its pipeline includes programs in areas such as respiratory syncytial virus (RSV).

1 investor

Enantios provides structural measurement services for molecules and proteins, as well as selling ROA (Raman Optical Activity) instruments for molecular characterization. The company serves researchers and companies working with chiral molecules, proteins, and antibodies.

1 investor

EncepHeal develops small-molecule medications targeting the dopamine transporter to treat stimulant addiction, including cocaine and methamphetamine, for which no FDA-approved treatments currently exist. The company uses allosteric modulators designed to reduce drug cravings without the addictive potential of earlier dopamine-targeting approaches.

1 investor

Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.

1 investor

Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration. Its initial focus is genetic subsets of Parkinson's disease, with plans to expand into sporadic Parkinson's and other dementias.

1 investor

Keenova is a specialty therapeutics company focused on rare, stigmatized, or unaddressed conditions across areas including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care. Par Health develops generic pharmaceuticals, sterile injectables, and active pharmaceutical ingredients with U.S.-based manufacturing capabilities.

1 investor

Novartis is a pharmaceutical company developing breakthrough medicines across therapeutic areas including oncology and cardiovascular disease.

1 investor

Endodiag develops non-invasive diagnostic tests based on blood biomarkers to identify endometriosis in women, addressing a condition currently requiring surgical diagnosis. The company also creates solutions to map patient disease for personalized treatment and fertility management.

1 investor

Endolipid Therapeutics is a biotech developing SHBG-mimicking peptides aimed at reducing ectopic fat accumulation to treat conditions such as fatty liver disease and NASH, as well as cellulite. Its work spans therapeutic and dermocosmetic applications.

1 investor

EndoProTech develops anti-inflammatory liposomes designed to modify the composition of cell plasma membranes and reduce microvascular dysfunction following ischemia/reperfusion injury. Its research targets reducing infarct size after myocardial infarction while preserving tissue viability and shortening recovery time.

1 investor

EndoStim develops a neurostimulation medical device system for treating drug-resistant gastroesophageal reflux disease (GERD) by restoring esophageal function while preserving normal anatomy.

1 investor

EndoVia develops a precision oncology platform that combines experimental biology with computational modeling to match cannabinoid-based cancer treatments to individual patients. It maps cannabinoid and extract libraries against biological targets, uses subtype-specific tumor models and multi-omics profiling, and builds predictive network and digital-twin models to guide therapeutic development.

1 investor

Early-stage oncology company developing a breakthrough siRNA platform to target undruggable cancer pathways.

1 investor

Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications. The company was founded by veteran biotherapeutics developers and focuses on unlocking therapeutic potential through its differentiated technology platform.

1 investor

Engine Bio presents itself as a company working on new cancer medicines.

1 investor

Enjamb develops an agentic AI platform for biopharma R&D teams that automates drug discovery, trial execution, and regulatory filings. The platform integrates with existing systems to support programs from early discovery through FDA approval.

1 investor

1 investor